Ysios Capital joined Adcendo's $135M Series B round, the EU's largest in biotech this year, enabling Adcendo to advance its cancer-targeting ADC pipeline. Based in Spain,...
Ysios Capital, specializing in biotech investments, will invest $157 million in Engrail Therapeutics, joining a syndicate led by F-Prime Capital. Engrail, founded in 2019, focuses on...